An initiative to enter the contract research, development and manufacturing (CRDMO) business for mid-molecule drugs through the establishment of シンクレスト株式会社, jointly funded with Yokogawa Electric Corporation. A valuation loss on shares of an affiliated company has also been recorded due to a decline in the value of the investment.